Lithium, Inflammation and Neuroinflammation with Emphasis on Bipolar Disorder—A Narrative Review
International Journal of Molecular Sciences · 11.12.2024 · 25 (24) · 13277
DOI: 10.3390/ijms252413277 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift International Journal of Molecular Sciences, online erschienen am 11.12.2024. Verfasst von Odeya Damri und 1 weiteren Autor:innen. Beteiligte Einrichtung: Department of Clinical Biochemistry and Pharmacology, Faculty of Health Sciences, Zlotowski Center for Neuroscience and Zelman Center-The School of B…. Hauptthemen laut MEDLINE: Bipolar Disorder, Inflammation. Die Arbeit wurde bisher 29-mal zitiert (Crossref) und nennt 84 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: The National Institute for Psychobiology in Israel.
Abstract (Originalsprache)
This narrative review examines lithium’s effects on immune function, inflammation and cell survival, particularly in bipolar disorder (BD) in in vitro studies, animal models and clinical studies. In vitro studies show that high lithium concentrations (5 mM, beyond the therapeutic window) reduce interleukin (IL)-1β production in monocytes and enhance T-lymphocyte resistance, suggesting a protective role against cell death. Lithium modulates oxidative stress in lipopolysaccharide (LPS)-activated macrophages by inhibiting nuclear factor (NF)-ƙB activity and reducing nitric oxide production. At therapeutically relevant levels, lithium increased both pro-inflammatory [interferon (INF)-γ, IL-8 and tumor necrosis factor (TNF)-α)] and anti-inflammatory (IL-10) cytokines on whole blood supernatant culture in healthy volunteers, influencing the balance of pro- and anti-inflammatory responses. Animal models reveal lithium’s potential to alleviate inflammatory diseases by reducing pro-inflammatory cytokines and enhancing anti-inflammatory responses. It also induces selective macrophage death in atherosclerotic plaques without harming other cells. In primary rat cerebellum cultures (ex vivo), lithium prevents neuronal loss and inhibits astroglial growth, impacting astrocytes and microglia. Clinical studies show that lithium alters cytokine profiles and reduces neuroinflammatory markers in BD patients. Chronic treatment decreases IL-2, IL-6, IL-10 and IFN-γ secretion from peripheral blood leukocytes. Lithium response correlates with TNF-α levels, with poor responders showing higher TNF-α. Overall, these findings elucidate lithium’s diverse mechanisms in modulating immune responses, reducing inflammation and promoting cell survival, with significant implications for managing BD and other inflammation-related conditions. Yet, to better understand the drug’s impact in BD and other inflammatory/neuroinflammatory conditions, further research is warranted to appreciate lithium’s therapeutic potential and its role in immune regulation.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Clinical Biochemistry and Pharmacology, Faculty of Health Sciences, Zlotowski Center for Neuroscience and Zelman Center-The School of Brain Sciences and Cognition, Ben-Gurion University of the Negev, Beer-…
Förderung
- The National Institute for Psychobiology in Israel
Zitieren
APA
Damri, O., & Agam, G. (2024). Lithium, Inflammation and Neuroinflammation with Emphasis on Bipolar Disorder—A Narrative Review. International Journal of Molecular Sciences, 25(24), 13277. https://doi.org/10.3390/ijms252413277
Vancouver
Damri O, Agam G. Lithium, Inflammation and Neuroinflammation with Emphasis on Bipolar Disorder—A Narrative Review. International Journal of Molecular Sciences. 2024;25(24):13277. doi:10.3390/ijms252413277
BibTeX
@article{Damri2024,
author = {Damri, Odeya and Agam, Galila},
title = {Lithium, Inflammation and Neuroinflammation with Emphasis on Bipolar Disorder—A Narrative Review},
journal = {International Journal of Molecular Sciences},
year = {2024},
volume = {25},
number = {24},
pages = {13277},
doi = {10.3390/ijms252413277}
}
EUVIMED